winstrol v

Pharmacological action winstrol v has a combined non-selective .beta. 1 – .beta. 2 – and α 1 – blocking action. The drug does not have its own sympathomimetic activity. It has membrane stabilizing properties. Due to the blockade of β-adrenergic receptors of the heart can decrease blood pressure, cardiac output and heart rate urszhatsya. winstrol v suppresses the renin-angiotensin-aldosterone system blockade by .beta.-adrenergic receptors of the kidneys, causing a reduction in plasma renin activity. Α-adrenoceptor blocking, the drug can cause expansion of peripheral blood vessels, thereby reducing systemic vascular resistance. The combination of β-adrenoceptor blockade and vasodilation provides the following effects: in patients with arterial gipergenziey – lowering blood pressure; in patients with coronary heart disease – anti-ischemic and anti-anginal action; in patients with left ventricular dysfunction and circulatory failure -blagopriyatno affects hemodynamic parameters increases left ventricular ejection fraction and reduces its size. Pharmacokinetics winstrol v is rapidly absorbed from the gastrointestinal tract. It has a high lipophilicity. The maximum concentration in blood is reached after 1-1.5 hours. The half-life is 6-10 hours. Associated with the plasma protein to 95-99%. The bioavailability of the drug 24-28%. Food intake has no effect on bioavailability. It is metabolized in the liver with the formation of a number of active metabolites – 60-75% of the adsorbed drug is metabolized at the first “pass” through the liver. The metabolites have a strong antioxidant and adrenoceptor blocking action. Excretion of the drug from the body is via the gastrointestinal tract. In case of violation of renal function the pharmacokinetic parameters of winstrol v did not change significantly. In patients with impaired liver function systemic bioavailability of winstrol v is increased by reducing the metabolism at the first “pass” through the liver. In severe hepatic dysfunction, winstrol v is contraindicated. winstrol v crosses the placental barrier, excreted in breast milk.

Indications

  • Arterial hypertension (monotherapy or combination with diuretics)
  • Chronic heart failure (in combination therapy)
  • Coronary heart disease: stable angina.

 

Contraindications
: Hypersensitivity to winstrol v or other components of the drug, acute and chronic heart failure (decompensation), severe hepatic insufficiency, atrioventricular block II-III century., Bradycardia (less than 50 beats / min), sick sinus syndrome, hypotension (systolic blood pressure less than 85 mm Hg. Art.), cardiogenic shock, chronic obstructive pulmonary disease, the age of 18 years (effectiveness and safety have been established).

Precautions
angina Prinzmetal, thyrotoxicosis, occlusive peripheral vascular disease, pheochromocytoma, psoriasis, renal failure, atrioventricular block I degree, extensive surgery and general anesthesia, diabetes, Hypogeum likemiya, depression, myasthenia gravis.

Pregnancy and lactation
Controlled trials of winstrol v in pregnant women has not been conducted, therefore, use of the drug in these patients is only possible in cases where the benefit to the mother outweighs the potential risk to the fetus. Do not breastfeed during treatment with winstrol v.

Dosage and administration
. Inside, regardless of meals Hypertension The initial dose is 6.25 – 12.5 mg 1 time per day during the first two days of treatment. Then 25 mg 1 time per day. When failure antihypertensive effect after 2 weeks of therapy, the dose can be increased by 2 times. The maximum recommended daily dose is 50 mg 1 time per day (possibly divided into 2 admission). Coronary heart disease The initial dose is 12.5 mg 2 times a day during the first two days of treatment. Then 25 mg 2 times a day. At insufficiency antianginal effect after 2 weeks of therapy, the dose may be increased by 2 times. The maximum recommended daily dose is 100 mg per day, divided into 2 admission. Congestive heart failure Dose picked individually, under the close supervision of a physician. The recommended starting dose is 3.125 mg, 2 times a day for 2 weeks. With good tolerance dose increased at intervals of at least 2 weeks to 6.25 mg 2 times a day, then to 12.5 mg 2 times a day, then – to 25 mg 2 times a day. The dose should be increased to the maximum, which is well tolerated by patients. In patients weighing less than 85 kg target dose is 50 mg per day; in patients weighing more than 85 kg target dose of 75 – 100 mg per day.

Side effect On the part of the central nervous system: dizziness, headache (usually not severe and early treatment), loss of consciousness, myasthenia gravis (usually at the beginning of the treatment), fatigue, depression, sleep disturbance, paresthesia. Cardio-vascular system : bradycardia, orthostatic hypotension, atrioventricular block II-III Article rarely – a violation of the peripheral circulation, the progression of heart failure (during increasing doses), lower limb edema, angina, marked reduction in blood pressure.. From the digestive system: dry mouth, nausea , diarrhea or constipation, vomiting, abdominal pain, loss of appetite, increased activity of “liver” transaminases. Hematopoietic system: rarely – thrombocytopenia, leukopenia. On the part of metabolism: increased body mass index, glucose dysregulation. allergic reactions: skin allergic reactions, exacerbation of psoriasis, nasal congestion. The respiratory system: dyspnea, and bronchospasm (in predisposed patients). Other: visual disturbances, reduced lacrimation, flu-like symptoms, sneezing, myalgia, arthralgia, pain in the limbs, “intermittent” claudication, rarely violation urination, renal failure.

Overdose Symptoms: lowering blood pressure (accompanied by dizziness or syncope), bradycardia. You may experience shortness of breath due to bronchospasm and vomiting. In severe cases, possible cardiogenic shock, respiratory failure, confusion, conduction abnormalities. Treatment: should be monitored and corrected vital parameters, if necessary – in the ICU. Treatment – symptomatic. It is advisable to use intravenous Mr. anticholinergics (atropine), adrepomimetikov (epinephrine, norepinephrine).

 

Interaction with other drugs
, winstrol v may potentiate the effect of other simultaneously received antihypertensive drugs or drugs that have a hypotensive effect (nitrates).
When combined winstrol v and diltiazem may develop cardiac conduction and hemodynamic instability.
At the same time taking winstrol v and digoxin increases the concentration of the latter and may increase atrioventricular conduction time. winstrol v may potentiate the action of insulin and oral hypoglycemic agents, and the symptoms of hypoglycaemia (especially tachycardia) may be masked, so diabetic patients is recommended regular monitoring of blood sugar levels.
Inhibitors mikrosomalnogo oxidation (cimetidine) increase, and inductors (phenobarbital, rifampicin) weaken hypotensive effect of winstrol v. Drugs that reduce the content of catecholamines (reserpine, monoamine oxidase inhibitors), increase the risk of hypotension and bradycardia.
At simultaneous application of cyclosporine increased the concentration of the latter (recommended correction daily dose cyclosporine).
Co-administration of Clonidine may potentiate antihypertensive and urezhayugtsy heart rate winstrol v effects.
Common anesthetics enhance the negative inotropic and hypotensive effects of winstrol v.

Specific guidance
Therapy should be carried out continuously and should not cease abruptly, especially in patients with coronary heart disease since it may lead to a deterioration of the underlying disease. If necessary, the reduction in dose should be gradual, in 1-2 weeks.
At the beginning of therapy or Vedikardolom with increasing doses of the drug in patients, particularly the elderly, may experience excessive reduction in blood pressure, especially when standing up. Needed correction doses. In patients with chronic heart failure in the selection of a dose may increase in heart failure symptoms, the appearance of edema. It is not necessary to increase the dose Vedikardola, recommended the appointment of high doses of diuretics until the stabilization of the patient.
It is recommended constant monitoring of ECG and blood pressure, while the appointment Vedikardola and blockers “slow” calcium channels, derivatives fenilalkilamina (verapamil) and benzodiazepines (diltiazem), and and -. with antiarrhythmics class I
recommended to monitor renal function in patients with chronic renal failure, hypotension and congestive heart failure. In case of surgery using general anesthesia should notify the anesthesiologist prior therapy Vedikardolom. Vedikardol not affect the concentration of glucose in the blood and does not cause tolerance test indicators of changes in glucose in patients with NIDDM.
During treatment, to avoid the use of ethanol.
Patients with pheochromocytoma before therapy is necessary to assign the alpha blockers.
Patients who wear contact lenses should be taken into account that the drug may cause a reduction in tearing.
it is not recommended to drive at the beginning of therapy and when the dose is increased Vedikardola. It should refrain from other activities related to the necessity of high concentration and rapid psychomotor reactions. buy anabolic steroids online bruce lee’s workout anabolic steroids online uk